Article

One and Five-Year Mortality Risk Prediction in Patients with Moderate and Severe Aortic Stenosis

Sameh Yousef 1, Andrea Amabile 1, Huang Huang 2, Ritu Agarwal 3, Saket Singh 1, Chirag Ram 1, Rita K. Milewski 1, Roland Assi 1, Yawie Zhang 2, Markus Krane 1, Arnar Geirsson 1 and Prashanth Vallabhajosyula 1,*

1 Division of Cardiac Surgery, Yale School of Medicine, New Haven, CT 06510, USA; samheh.yousef@yale.edu (S.Y.); andrea.amabile@yale.edu (A.A.); saket.singh@yale.edu (S.S.); chirag.ram@yale.edu (C.R.); rita.milewski@yale.edu (R.K.M.); roland.assi@yale.edu (R.A.); markus.krane@yale.edu (M.K.); arnar.geirsson@yale.edu (A.G.)

2 Section of Surgical Outcomes and Epidemiology, Yale School of Public Health, New Haven, CT 06510, USA; huang.huang@yale.edu (H.H.); yawie.zhang@yale.edu (Y.Z.)

3 Joint Data Analytics Team, Information Technology Service, Yale University, New Haven, CT 06520, USA; ritu.agarwal@yale.edu

* Correspondence: prashanth.vallabhajosyula@yale.edu; Tel./Fax: +1-203-785-5000

Abstract: (1) Background: Our goal was to develop a risk prediction model for mortality in patients with moderate and severe aortic stenosis (AS). (2) Methods: All patients aged 40–95 years, with echocardiographic evidence of moderate and severe AS at a single institution, were studied over a median of 2.8 (1.5–4.8) years, between 2013–2018. Patient characteristics and mortality were compared using Chi-squares, t-tests, and Kaplan–Meier (KM) curves, as appropriate. The risk calculation for mortality was derived using the Cox proportional hazards model. A risk score was calculated for each parameter, and the total sum of scores predicted the individualized risks of 1-and 5-year mortality. (3) Results: A total of 1991 patients with severe and 2212 with moderate AS were included. Severe AS patients were older, had a lower ejection fraction %, were more likely to be Caucasian, and had lower rates of obesity and smoking, but had higher rates of cardiac comorbidities and AVR (49.3% vs. 2.8%, p < 0.0001). The unadjusted overall mortality was 41.7% vs. 41%, p = 0.6530, and was not different using KM curves (log rank, p = 0.0853). The models included only patients with complete follow-up (3966 in the 1-year, and 816 in the 5-year model) and included 13 variables related to patient characteristics, degree of AS, and AVR. The C-statistic was 0.75 and 0.72 for the 1-year and the 5-year models, respectively. (4) Conclusions: Patients with moderate and severe AS experience high morbidity and mortality. The usage of a risk prediction model may provide guidance for clinical decision making in complex patients.

Keywords: aortic; stenosis; mortality; risk; prediction

1. Introduction

Calcific aortic stenosis (AS) is the most common valvular heart disease in Western countries, with at least one in every eight people suffering from moderate or severe disease [1,2]. AS is projected to increase in conjunction with the overall aging of the population and the persistent high burden of atherosclerotic risk factors [3]. The 2-year survival rate for severe symptomatic AS is less than 50%, worse than the mortality of many malignancies [4]. Moreover, patients with moderate AS experience high mortality according to recent reports [5–8].

AS primarily affects the elderly and shares similar biological and etiological risk factors with atherosclerotic diseases. Therefore, multiple comorbidities are usually prevalent in patients suffering from AS [9–11].
In such a complex patient population, the identification and integration of relevant prognostic information into the decision-making process is crucial. A better knowledge concerning prognostic outcome would allow for individualized patient encounters in the era of precision medicine. Yet, only few prognostic models have been developed for patients with AS. Most importantly, the current models have been limited to highly selected subgroups and are not widely applicable in practice: several reports focused on the mortality risk of medical management of AS classified by degree of stenosis, while others provided risk calculators for mortality after aortic valve replacement (AVR) [12–14].

Equally important is the fact that there is no proven medical therapy able to reverse or reduce the disease progression, and AVR continues to be the only effective treatment option that increases both survival and quality of life in patients with AS [15–18]. Still, a significant number of patients with severe AS do not undergo intervention [4,19,20].

Regarding this effect, we leveraged a large echocardiography database to develop a prediction model to better characterize risk factors of mortality, based on readily available information on demographics, comorbidity, and degree of stenosis. Furthermore, we aimed to analyze patient benefits from AVR intervention in the background of individualized risk profile stratification.

**2. Materials and Methods**

**2.1. Data Source and Patient Population**

The Institutional Review Board at Yale University approved this study. Yale New Haven Health System is a tertiary care center serving the community of the greater New Haven area, as well as a large portion of the population of the state of Connecticut (characterized by multiple ethnic backgrounds, age groups, and comorbidity profiles), in addition to the out-of-state referrals. All echocardiography data (both transthoracic and transesophageal) and electronic health records were queried for patients \( \geq 18 \) years old who had at least one study during the calendar years of 2013 to 2018.

**2.2. Analytic Cohort Building**

Given that AS is rare before age 40, patients less than 40 years old at the time of their initial study were excluded. Patients older than 95 years old at the time of their initial study were also excluded because diagnosis of AS and AVR adds minimal benefit to longevity in such an old age group.

Using the echocardiography reports and International Classification of Disease (ICD-10) codes, we excluded patients with a prosthetic aortic valve in their initial echocardiography during the study period, patients with AV pathology other than calcific AS (i.e., rheumatic AS, endocarditis, hypertrophic obstructive cardiomyopathy (HOCM), moderate and severe AI and aortic valve tumor), patients who had AVR as part of an aortic aneurysm or dissection repair, and patients who received heart transplantation or ventricular assist device treatment. Studies missing all AV doppler parameters were also excluded (Figure 1).

**2.3. Aortic Stenosis Severity**

Based on echocardiography parameters clinically used to define AS (namely aortic valve area (AVA), dimensionless valve index (DVI), mean pressure gradient across the valve (PG-mean), and the maximum flow velocity across the valve (V-max)), patients were categorized into: severe AS (AVA \( \leq 1 \) cm\(^2\), or DVI \( \leq 0.25\), or V-max \( \geq 4 \) m/s, or PG-mean \( \geq 40 \) mmHg) and moderate AS (AVA 1–1.5 cm\(^2\), or DVI 0.25–0.5, or V-max 3–4 m/s, or PG-mean 20–40 mmHg) [21]. When multiple data were available, the most severe values were used to assess the degree of AS.
Figure 1. Cohort-building study flow diagram. Patients less than 40 and more than 95 years old, patients missing all echocardiographic parameters (AVA, DVI, V-max, PG-mean), and patients with valve pathology other than calcific (rheumatic, HOCM, tumor, endocarditis, and patients who had AVR as a part of aneurysm or dissection repair) were excluded.

2.4. Patient Characteristics

Age was defined as the age at the time of the index echocardiography date. Race was categorized into Caucasian, African American, and other races. Baseline body surface area (BSA) was used. Smoking was defined by a positive history of more than 5 years of smoking. Comorbidities (hypertension, diabetes mellitus, dyslipidemia, heart failure, chronic kidney disease, coronary artery disease, chronic obstructive pulmonary disease, stroke, peripheral vascular disease, atrial fibrillation) were defined by ICD-10 codes (Appendix A).

2.5. Aortic Valve Replacement

Using unique identifiers (i.e., medical record number, last name, first name, and date of birth), patients with AS were linked to our institutional Society of Thoracic Surgeries (STS) database and the STS/ACC TVT TAVR registry.

2.6. Mortality Data

Death dates were extracted from the Connecticut State Vital Statistics database by linking the patient’s first and last name and date of birth on the date of censoring, 23 January 2020. The median follow-up time and inter-quartile range were 2.8 (1.52–4.8) years.

2.7. Statistical Analysis

Categorical variables were summarized as counts and percentages, while continuous variables were summarized as means and standard deviations (SD). Differences between the study groups (moderate vs. severe AS) were tested using the Student t-test for continuous variables and the Chi-square test for categorical variables. Mortality of the patients with moderate AS was compared to patients with severe AS using Kaplan–Meier (KM) curves.

Variables predicting risk of 1- and 5-year mortality were evaluated by Cox proportional hazards models in moderate and severe AS patients, with 1- and 5-year follow-up, respectively. A total of 237 patients who were followed-up for less than 1 year at the end of follow-up have been excluded from the 1-year mortality model, resulting in 3966 patients for the prediction analysis, while 3387 patients who were followed less than 5 years at the end of follow-up have been excluded from the 5-year mortality model, resulting in 816 patients. Candidate variables include information on demographics (age at diagnosis, sex, and race/ethnicity), comorbidities, AVR, and severity of AS.

Age was used as a continuous variable and as the age-squared term to further evaluate the nonlinear relationship between age and mortality. The covariates included in the
final prediction model were selected by a combination of stepwise regression and Akaike information criteria [22]. The risk score of each parameter was calculated by dividing the corresponding β coefficient by the lowest β value and rounding to the closest integer. Risk scores of 1- and 5-year mortality for each individual patient were calculated as the sum of all parameter scores. Estimated risks of 1- and 5-year mortality were calculated based on the individual total risk score and average 1- and 5-year survival $S(t = 1 \text{ or } 5)$ [23]. Model performance was assessed using the C-index for discrimination ability and the visual estimation of the predictiveness curve for calibration.

The $p$ value of $<0.05$ was defined a priori and was used to define statistically significant differences. Analysis was conducted using Microsoft Excel 2019 and Prism 8.2 (GraphPad Software, San Diego, CA, USA) for descriptive analyses and SAS 9.4 (SAS Institute Inc, Cary, NC, USA) and R 3.6.3 (R Foundation, Vienna, Austria) for survival analysis.

3. Results

Between 2013 and 2018, 48,524 patients $\geq$ 18 years old underwent at least one echocardiography study, with a total number of 132,116 studies available. A total of 38,791 patients were included in the final analysis after excluding patients $<40$ or $>95$ years old, patients with a prosthetic valve on their first study during the study period, patients with AV pathology other than degenerative (i.e., endocarditis, HOCM, moderate or higher aortic insufficiency) and studies with no single parameter available to assess AS severity (Figure 1). When stratified by degree of AS, 5.7% of them ($n = 2212$) had moderate AS, and 5.1% ($n = 1991$) had severe AS.

3.1. Patient Characteristics and Comorbidities

Table 1 summarizes patient characteristics: patients with severe AS were more likely to be older, Caucasian, with lower BSA, lower EF%, higher rates of cardiac comorbidities (CHD, Afib, and CHF), and were less likely to have a history of obesity and stroke. The rates of DM, dyslipidemia, CKD, COPD, PVD, and hypertension were not statistically different between moderate and severe AS patients.

Table 1. Characteristics of patients with AS on their first echocardiography during the study period *

|                       | Moderate AS $n = 2212$ | Severe AS $n = 1991$ | $p$   |
|-----------------------|------------------------|----------------------|-------|
| Age/year              | 76.09 ± 11.5           | 80.26 ± 10.6         | <0.0001|
| Sex (male)            | 1178 (53.3%)           | 1043 (52.4%)         | 0.5730 |
| Race—Caucasian        | 1843 (83.3%)           | 1764 (88.6%)         |       |
| Race—African American | 206 (9.3%)             | 119 (6%)             | <0.0001|
| Race—Other            | 156 (7.1%)             | 108 (5.4%)           |       |
| BSA (m$^2$)           | 1.89 ± 0.28            | 1.86 ± 0.28          | <0.0001|
| Smoking               | 694 (31.4%)            | 560 (28.1%)          | 0.0216 |
| Ejection fraction (%) | 57.01 ± 14             | 56.68 ± 14.62        | <0.0001|
| Diabetes mellitus     | 726 (32.8%)            | 615 (30.9%)          | 0.1797 |
| Dyslipidemia          | 1285 (58.1%)           | 1194 (60%)           | 0.2166 |
| Obesity               | 181 (8.2%)             | 121 (6.1%)           | 0.0083 |
| CKD                   | 345 (15.6%)            | 328 (16.5%)          | 0.4387 |
| Stroke                | 303 (13.7%)            | 226 (11.4%)          | 0.0220 |
| Atrial fibrillation   | 555 (25.1%)            | 602 (30.2%)          | 0.0002 |
| CHD                   | 751 (34%)              | 834 (41.9%)          | <0.0001|
| COPD                  | 359 (16.2%)            | 323 (16.2%)          | 0.9953 |
| PVD                   | 222 (10%)              | 230 (11.6%)          | 0.1132 |
| Heart failure         | 409 (18.5%)            | 453 (22.8%)          | 0.0006 |
| Hypertension          | 1708 (77.2%)           | 1560 (78.4%)         | 0.3760 |
Table 1. Cont.

| Risk Factor               | Patients with 1-Year Follow-up | Patients with 5-Year Follow-up |
|---------------------------|-------------------------------|-------------------------------|
|                           | Number | β Coefficient | p-Value | Hazard Ratio | 95% CI | Number | β Coefficient | p-Value | Hazard Ratio | 95% CI |
| AV intervention           | 2212   | 61 (2.8%)     | <0.0001 | 1.02         | 1.016–1.022 | 1991   | 931 (46.8%)   | <0.0001 | 1.02         | 1.018–1.030 |
| Peak Velocity (m/sec)     | 2.82 ± 0.65 | 4.1 ± 0.34 | <0.0001 | 1.08         | 0.98–1.19  | 2.82 ± 0.65 | 4.1 ± 0.34 | <0.0001 | 1.08         | 0.98–1.19  |
| Mean Gradient (mm Hg)     | 18.7 ± 8.2  | 41 ± 5.6     | <0.0001 | 0.92         | 0.77–1.11  | 18.7 ± 8.2  | 41 ± 5.6     | <0.0001 | 0.92         | 0.77–1.11  |
| AVA (cm²)                 | 1.4 ± 0.28   | 0.78 ± 0.22  | <0.0001 | 0.74         | 0.59–0.92  | 1.4 ± 0.28   | 0.78 ± 0.22  | <0.0001 | 0.74         | 0.59–0.92  |
| DVI                       | 0.46 ± 0.13   | 0.25 ± 0.08  | <0.0001 | 0.81         | 0.67–1.00  | 0.46 ± 0.13   | 0.25 ± 0.08  | <0.0001 | 0.81         | 0.67–1.00  |
| LVDD (cm)                 | 4.72 ± 0.81   | 4.63 ± 0.79  | <0.0001 | 1.00         | 0.99–1.01  | 4.72 ± 0.81   | 4.63 ± 0.79  | <0.0001 | 1.00         | 0.99–1.01  |
| LVISD (cm)                | 3.4 ± 0.58    | 3.2 ± 0.88  | 0.0004 | 0.78         | 0.64–0.94  | 3.4 ± 0.58    | 3.2 ± 0.88  | 0.0004 | 0.78         | 0.64–0.94  |
| Overall mortality         | 907 (41%)    | 830 (41.7%)  | 0.6530 | 1.00         | 0.99–1.01  | 907 (41%)    | 830 (41.7%)  | 0.6530 | 1.00         | 0.99–1.01  |

*Continuous variables are represented as mean ± SD, and categorical variables are represented as number (%). Comparisons of continuous variables by Student t-test and categorical variables by Chi square test.

Rates of AVR were different: 2.8% (n = 61) of moderate AS had AVR (all SAVR), while 46.8% (n = 931) with severe AS had AVR (TAVR = 63.5% and SAVR = 36.5%).

BSA: body surface area; CKD: chronic kidney disease; CHD: chronic heart disease; COPD: chronic obstructive pulmonary disease; PVD: peripheral vascular disease; AVA: aortic valve area; DVI: dimensionless valve index; LVDD: left ventricular internal end diastolic diameter; LVISD: left ventricular internal end systolic diameter.

3.2. Comparative Mortality of Patients with Moderate and Severe AS

The unadjusted all-cause mortality rate throughout the study period was not statistically different in moderate vs. severe AS (moderate AS = 41%, and severe AS = 41.7%, p = 0.6530). The overall mortality rate in patients with moderate AS who had AVR was 31%, and in patients with moderate AS who did not undergo AVR, it was 41.3%. In patients with severe AS, the mortality rate in patients with AVR was 26% and in patients without AVR, it was 55%. In a time-to-event analysis using KM curves, patients with moderate AS had similar mortality rates compared to patients with severe AS (Figure 2).

![Figure 2](image-url)

**Figure 2.** Mortality of patients with moderate and severe AS. Unadjusted mortality using Kaplan–Meier curves for 2 groups (moderate AS (blue curve) vs. severe AS (red curve)).

3.3. Predicted Survival among Patients with Moderate and Severe AS

Variables selected as predictors for 1- and 5-year mortality and corresponding β coefficients are summarized in Table 2.
| Risk Factor | Patients with 1-Year Follow-up | Patients with 5-Year Follow-up |
|-------------|-------------------------------|-------------------------------|
|             | Number | β Coefficient | p-Value | Hazard Ratio | 95% CI | Number | β Coefficient | p-Value | Hazard Ratio | 95% CI |
| Age *       | 3966   | 0.0188       | <0.0001 | 1.02       | 1.016–1.022 | 816     | 0.0237       | <0.0001 | 1.02       | 1.018–1.030 |
| Gender      |        |              |         |            |         |        |              |         |            |        |
| Female      | 1866   | ref.         |         | 1.00       |         |        |              |         |            |        |
| Male        | 2100   | 0.0792       | 0.11    | 1.08       | 0.98–1.19 |        |              |         |            |        |
| Race/ethnicity |     |              |         |            |         |        |              |         |            |        |
| Caucasian   | 3418   | ref.         |         | 1.00       |         | 713     | ref.         |         | 1.00       |         |
| African American | 296 | −0.0788   | 0.41    | 0.77–1.11 | 51     | −0.0053  | 0.98       | 1.00       | 0.69–1.43 |
| Another race| 252    | −0.3039      | 0.071   | 0.59–0.92 | 52     | −0.4021  | 0.040      | 0.67       | 0.46–0.98 |
| Comorbidity |        |              |         |            |         |        |              |         |            |        |
| Diabetes mellitus | | | | | | | | | | |
| No          | 2711   | ref.         |         | 1.00       |         | 555     | ref.         |         | 1.00       |         |
| Yes         | 1255   | 0.1690       | 0.0018  | 1.18       | 1.07–1.32 | 261     | 0.3677       | 0.0002    | 1.44       | 1.19–1.75 |
| Dyslipidemia |        |              |         |            |         |        |              |         |            |        |
| No          | 1642   | ref.         |         | 1.00       |         | 335     | ref.         |         | 1.00       |         |
| Yes         | 2324   | −0.1965      | 0.0001  | 0.82       | 0.74–0.91 | 481     | −0.2542      | 0.0092    | 0.78       | 0.64–0.94 |
| Obesity     |        |              |         |            |         |        |              |         |            |        |
| No          | 3692   | ref.         |         | 1.00       |         |        |              |         |            |        |
| Yes         | 274    | −0.1599      | 0.14    | 0.85       | 0.69–1.05 |        |              |         |            |        |
| CKD         |        |              |         |            |         |        |              |         |            |        |
| No          | 3340   | ref.         |         | 1.00       |         | 693     | ref.         |         | 1.00       |         |
| Yes         | 626    | 0.3828       | <0.0001 | 1.47       | 1.30–1.66 | 123     | 0.4721       | <0.0001   | 1.60       | 1.28–2.01 |
| Stroke      |        |              |         |            |         |        |              |         |            |        |
| No          | 3462   | ref.         |         | 1.00       |         | 696     | ref.         |         | 1.00       |         |
| Yes         | 504    | 0.1899       | 0.0055  | 1.21       | 1.06–1.38 | 120     | 0.2202       | 0.061     | 1.25       | 0.99–1.57 |
| COPD        |        |              |         |            |         |        |              |         |            |        |
| No          | 3317   | ref.         |         | 1.00       |         | 654     | ref.         |         | 1.00       |         |
| Yes         | 649    | 0.3161       | <0.0001 | 1.37       | 1.22–1.55 | 162     | 0.1632       | 0.13      | 1.18       | 0.95–1.46 |
| Heart failure |      |              |         |            |         |        |              |         |            |        |
| No          | 3144   | ref.         |         | 1.00       |         | 570     | ref.         |         | 1.00       |         |
| Yes         | 822    | 0.2129       | 0.0002  | 1.24       | 1.11–1.38 | 246     | 0.2031       | 0.036     | 1.23       | 1.01–1.48 |
| Hypertension |      |              |         |            |         |        |              |         |            |        |
| No          | 892    | ref.         |         | 1.00       |         | 183     | ref.         |         | 1.00       |         |
| Yes         | 3074   | −0.1066      | 0.087   | 0.80–1.02  | 633     | −0.3824  | 0.0007      | 0.68      | 0.55–0.85  |         |

Table 2. Cox proportional regression coefficients and hazard ratios for AS patients with 1-year and 5-year follow-up.
Scores of risk factors (Table 3, Figure 3) indicated that AVR was the most significant negative predictor of both 1- and 5-year mortality. This was reflected in the $\beta$ estimate ($-1.3$ for the 1-year and $-1.2$ for the 5-year model), the HR of mortality ($0.27$ CI $[0.23–0.31]$ for the 1-year and $0.29$ CI $[0.23–0.37]$ for the 5-year model), and the integer score ($-70$ for the 1-year and $-52$ for the 5-year model). The degree of stenosis was a predictor of mortality in the 1-year model, where severe AS in reference to moderate AS was associated with increased risk of mortality (HR = $1.4$ CI $[1.3–1.6]$), but not in the 5-year model (HR = $1.28$ CI $[0.98–1.5]$). Age was associated with incremental increase in mortality; for each 10 year increase in age, the risk of mortality increased by $2\%$. There was no difference in mortality according to gender, while race other than Caucasian and African American was a negative predictor of mortality. Among the comorbidities, CKD, HF, DM, history of stroke, and COPD were positive predictors of mortality, while hypertension, dyslipidemia, and history of obesity were negative predictors. (Table 2).

### Table 3. Score system for AS patients with 1-year and 5-year follow-up.

| Risk Factor | Patients with 1-Year Follow-up | Patients with 5-Year Follow-up |
|-------------|--------------------------------|-------------------------------|
|             | $\beta$ Coefficient | Score | $\beta$ Coefficient | Score |
| Age         | 0.0188              | 0     | 0.0237              | 0     |
| 40–49       |                     |       |                    |       |
| 50–59       | 0.0792              | 4     |                     | 4     |
| Gender      | Female                | ref.  | 0                   | ref.  |
|             | Male                   |       |                      | 4     |
| Race/ethnicity | Caucasian              | ref.  | 0                   | ref.  |
|             | African American       | $-0.0788$ | $-4$             | $-0.0053$ | $0$ |
|             | Other race             | $-0.3039$ | $-16$           | $-0.4021$ | $-17$ |
| Risk Factor          | Patients with 1-Year Follow-up | Patients with 5-Year Follow-up |
|---------------------|--------------------------------|--------------------------------|
|                     | β Coefficient | Score | β Coefficient | Score |
| Comorbidity         |                |       |                |       |
| Diabetes mellitus   | No ref.       | 0     | ref.           | 0     |
|                     | Yes 0.1690    | 9     | 0.3677         | 16    |
| Dyslipidemia        | No ref.       | 0     | ref.           | 0     |
|                     | Yes −0.1965   | −10   | −0.2542        | −11   |
| Obesity             | No ref.       | 0     |                |       |
|                     | Yes −0.1599   | −9    |                |       |
| CKD                 | No ref.       | 0     | ref.           | 0     |
|                     | Yes 0.3828    | 20    | 0.4721         | 20    |
| Stroke              | No ref.       | 0     | ref.           | 0     |
|                     | Yes 0.1899    | 10    | 0.2202         | 9     |
| COPD                | No ref.       | 0     | ref.           | 0     |
|                     | Yes 0.3161    | 17    | 0.1632         | 7     |
| Heart failure       | No ref.       | 0     | ref.           | 0     |
|                     | Yes 0.2129    | 11    | 0.2031         | 9     |
| Hypertension        | No ref.       | 0     | ref.           | 0     |
|                     | Yes −0.1066   | −6    | −0.3824        | −16   |
| AS Severity         | Moderate ref. | 0     | ref.           | 0     |
|                     | Severe 0.3721 | 20    | 0.1889         | 8     |
| Intervention        | No ref.       | 0     | ref.           | 0     |
|                     | Yes −1.3131   | −70   | −1.2336        | −52   |
Finally, the estimated cumulative risk of mortality was calculated as the sum of risk scores, and the cohort was further divided into risk groups according to the estimated risk of mortality (Table 4). The C-statistic was 0.75 and 0.72 for the 1-year and 5-year models, respectively. Visual assessment of the predictiveness curve supported good calibration (Appendix B).
### Table 4. Risk estimates of 1- and 5-year mortality for AS patients with 1-year and 5-year follow-up *

| Patients with 1-Year Follow-up | Estimate Risk of 1-Year Mortality | Total Score | Estimate Risk of 5-Year Mortality | Total Score |
|-------------------------------|-----------------------------------|-------------|-----------------------------------|-------------|
| Total Score                   |                                   |             |                                   |             |
| +111 to +90                   | 0.0201–0.0296                     | +96 to +90  | 0.0582–0.0668                     |
| −90 to −70                    | 0.0302–0.0429                     | −89 to −70  | 0.0683–0.1050                     |
| −69 to −50                    | 0.0437–0.0618                     | −69 to −50  | 0.1074–0.1633                     |
| −49 to −30                    | 0.0630–0.0888                     | −49 to −30  | 0.1669–0.2490                     |
| −29 to −10                    | 0.0904–0.1266                     | −29 to −10  | 0.2542–0.3688                     |
| −9 to 10                      | 0.1289–0.1790                     | −9 to 10    | 0.3757–0.5224                     |
| 11 to 30                      | 0.1820–0.2496                     | 11 to 30    | 0.5308–0.6949                     |
| 31 to 50                      | 0.2537–0.3418                     | 31 to 50    | 0.7035–0.8515                     |
| 51 to 70                      | 0.3470–0.4562                     | 51 to 70    | 0.8581–0.9533                     |
| 71 to 96                      | 0.4625–0.6296                     | 71 to 74    | 0.9566–0.9656                     |

* Average 1-year survival = 0.7310; 5-year survival = 0.4154.

### 4. Discussion

As the elderly population continues to expand, a better understanding of the mortality risk rendered by AS and associated comorbidities in this population is needed. Valvular intervention in this population has been shown to increase longevity and improve quality of life; therefore, AVR decisions need to be balanced with patient age, comorbidity burden, and quality of life. In our study, among the many studied parameters, the risk prediction model showed AVR to be the strongest negative predictor of mortality. Yet, a large fraction of patients did not undergo intervention. The low rate of AVR in patients with moderate AS (2.8% in this study) is understandable considering the current guidelines that recommend it as a class II-A indication for patients undergoing cardiac surgery for other indications [24], but the low rate of intervention in severe AS (43% in this study) underscores the gap that still exists in severe AS management. In reports before the era of TAVR, prohibitive surgical risk was the most common reason for lack of intervention [19,25,26]. The increasingly wider adoption of TAVR-enabled intervention in high surgical risk patients and its impact is reflected as a noted decline in national mortality from aortic stenosis [18]. In a more contemporary report in the TAVR era, 74% of patients with severe symptomatic AS who did not undergo intervention were not referred for evaluation [4], reflecting the need for increasing awareness and improved timely referral of AS patients.

To this effect, we report the development of a robust predictive model to help clinicians and patients make more informed decisions. At the point of care, it may be preferable to use individual survival probabilities calculated automatically by equations derived from the study model. These results would quantify risk as 1- and 5-year survival and thereby inform both the provider and the patient. Such an approach may incentivize provider recommendation of guideline-based care, as well as patient compliance.

For example, in a Caucasian male patient whose age is 78 and who has DM, CKD, and HF, and whose AS is severe, without AVR, this patient will have a sum of scores of 67 in the 1-year and 56 in the 5-year mortality models. This correlates with a 35–45% mortality risk within 1 year and a 85–95% mortality risk within 5 years. If the same patient undergoes AVR, the sum of scores will be -3 in the 1-year and 4 in the 5-year models. This correlates with a 10–20% mortality risk within the first year and a 38–52% mortality risk within 5 years. With these numbers available at the point of care, this patient will be able to understand the risks and make an informed decision.

In this cohort, patients with moderate AS were found to have high mortality approaching that of patients with severe AS; hence, they were included in the model. It is possible that even a moderate degree of AS could be detrimental in certain groups of patients.
This is shown in our model as the sum of scores, highlighting the role for individualized prognostic models that include many patient factors, in addition to the degree of stenosis. These results are clinically supported by data from the National ECHO Database of Australia [6]. Moreover, on a pathological level, using speckle tracking MRI, Ng AC et al., showed successive impairment of multidirectional myocardial function with increasing severity of AS [27].

To facilitate effective use of the model, 13 variables—chosen by the step wise selection function of the Cox models—were included in the final model, and an integer score for each parameter based on the beta estimate of the variable importance in the model was calculated. Using the Cox model in this analysis enabled us to account for the time-sensitive nature of mortality in this patient population. However, we still reported the 1- and 5-year risks to make it easier for patients to comprehend the risk of mortality in an objective numerical way during point-of-care conversations.

**Limitations**

This is an observational retrospective study that explores the prognostic significance of certain variables in patients with advanced AS. In this framework, causality cannot be established, and the interpretation is limited to a possible association of certain variables with mortality in this patient population. Further studies, preferably randomized control studies, are suggested to explore the impact of AVR in patients with moderate AS. The low rate of intervention in this study could be explained by the fact that TAVR was not fully employed during the early years of the study. However, contemporary reports show continued under-utilization of this resource, even in academic centers [28]. The prediction model presented in this study is based on claims data in the form of ICD10 codes, which limited our ability to include important factors in the model. For example, it not possible to extract data on functional status and frailty index from these claims data. Future work should consider these factors in the prognostic models.

5. **Conclusions**

In this study of echocardiograms obtained across a large health system encompassing various care settings, patients with severe, as well as moderate, AS experienced high morbidity and mortality. The prognostic model developed in this study has the potential to be used as an individualized mortality risk calculator during points-of-care.

**Author Contributions:** Conceptualization: S.Y. and P.V.; methodology: S.Y., A.A., H.H., R.A. (Ritu Agarwal), S.S., C.R., R.K.M., R.A. (Roland Assi), Y.Z., M.K., A.G. and P.V.; software: H.H., R.A. (Ritu Agarwal) and Y.Z.; validation: S.Y., A.A., H.H., R.A. (Ritu Agarwal), S.S., C.R., R.K.M., R.A. (Roland Assi), Y.Z., M.K., A.G. and P.V.; formal analysis: S.Y., H.H. and Y.Z.; investigation: S.Y., A.A., H.H., R.A. (Ritu Agarwal), S.S., C.R., R.K.M., R.A. (Roland Assi), Y.Z., M.K., A.G. and P.V.; data curation: S.Y., H.H. and R.A. (Ritu Agarwal); writing—original draft preparation: S.Y.; writing—review and editing: S.Y., A.A., H.H., R.A. (Ritu Agarwal), S.S., C.R., R.K.M., R.A. (Roland Assi), Y.Z., M.K., A.G. and P.V.; visualization: S.Y., A.A., H.H., R.A. (Ritu Agarwal), S.S., C.R., R.K.M., R.A. (Roland Assi), Y.Z., M.K., A.G. and P.V.; supervision: R.K.M., R.A. (Roland Assi), Y.Z., M.K., A.G. and P.V.; project administration: S.Y.; funding acquisition: n/a. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Yale University (protocol code 2000028791, date of approval 9 February 2020).

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** The authors acknowledge the investigators from the TAVR team at the Yale New Haven Hospital.
Conflicts of Interest: The authors declare no conflict of interest.

Appendix A

Table A1. ICD-10 codes used to define comorbidities.

| Disease                                         | ICD10 Code          |
|------------------------------------------------|---------------------|
| Aortic insufficiency                           | I35.1               |
| Atrial fibrillation                            | I48.91, I48.0       |
| Coronary artery disease                        | I25.10, I21.9, I25.5, I25.2 |
| Stroke                                         | I61.9, I63.9        |
| Chronic kidney disease                         | N18.6, N18.9, N18.3, N18.6, Z99.2 |
| Chronic obstructive pulmonary disease          | J44.9               |
| Endocarditis                                   | I38                 |
| Heart failure                                  | I50.9               |
| Heart transplant status                        | Z94.1               |
| Ventricular assisted device                    | Z95.811, Z95.812    |
| Hyperlipidemia                                 | E78.5, E78.00       |
| Hypertrophic obstructive cardiomyopathy        | H42.1, H42.2        |
| Hypertension                                   | I10                 |
| Obesity                                        | E66.9, E66.01       |
| Prosthetic heart valve                         | Z95.2, Z95.1        |
| Peripheral vascular disease                    | I73.9               |
| Diabetes mellitus                              | E10.9, E11.9, E11.65|

ICD-10: international classification of disease codes, version 10.

Appendix B

Predictiveness curves for 1- and 5-year mortality models.
References

1. Nkomo, V.T.; Gardin, J.M.; Skelton, T.N.; Gottdiener, J.S.; Scott, C.G.; Enriquez-Sarano, M. Burden of valvular heart diseases: A population-based study. *Lancet* 2006, 368, 1005–1011. [CrossRef]

2. Benjamin, E.J.; Virani, S.S.; Callaway, C.W.; Chamberlain, A.M.; Chang, A.R.; Cheng, S.; Chiueh, S.E.; Cushman, M.; Delling, F.N.; Deo, R.; et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. *Circulation* 2018, 137, e67–e492. [CrossRef] [PubMed]

3. Faggiano, P.; Frattini, S.; Zillioli, V.; Rossi, A.; Nistri, S.; Dini, F.L.; Lorusso, R.; Tomasi, C.; Cas, L.D. Prevalence of comorbidities and associated cardiac diseases in patients with valve aortic stenosis. Potential implications for the decision-making process. *Int. J. Cardiol.* 2012, 159, 94–99. [CrossRef] [PubMed]

4. Tang, L.; Gössl, M.; Ahmed, A.; Garberich, R.; Bradley, S.M.; Niikura, H.; Witt, D.; Pedersen, W.R.; Bae, R.; Lesser, J.R.; et al. Contemporary Reasons and Clinical Outcomes for Patients With Severe, Symptomatic Aortic Stenosis Not Undergoing Aortic Valve Replacement. *Circ. Cardiovasc. Inter. 2018, 11, e007220.* [CrossRef] [PubMed]

5. Lancellotti, P.; Magne, J.; Dulgeru, R.; Clavel, M.-A.; Donal, E.; Vannan, M.A.; Chambers, J.; Rosenhek, R.; Habib, G.; Lloyd, G.; et al. Outcomes of Patients With Asymptomatic Aortic Stenosis Followed Up in Heart Valve Clinics. *JAMA Cardiol.* 2018, 3, 1060–1068. [CrossRef] [PubMed]

6. Strange, G.; Stewart, S.; Celermajer, D.; Prior, D.; Scalia, G.M.; Marwick, T.; Ilton, M.; Joseph, M.; Codde, J.; Playford, D. Poor Long-Term Survival in Patients With Moderate Aortic Stenosis. *J. Am. Coll. Cardiol. 2019, 74, 1851–1863.* [CrossRef] [PubMed]

7. Rosenhek, R.; Klaar, U.; Schemper, M.; Scholten, C.; Heger, M.; Gabriel, H.; Binder, T.; Maurer, G.; Baumgartner, H. Mild and moderate aortic stenosis Natural history and risk stratification by echocardiography. *Eur. Heart J.* 2004, 25, 199–205. [CrossRef]

8. Otto, C.M. Aortic stenosis: Even mild disease is significant. *Eur. Heart J.* 2004, 25, 185–187. [CrossRef]

9. Rudolph, T.K.; Messika-Zeitoun, D.; Frey, N.; Thambirajah, J.; Serra, A.; Schulz, E.; Maly, J.; Aiello, M.; Lloyd, G.; Bortone, A.S.; et al. Impact of selected comorbidities on the presentation and management of aortic stenosis. *Open Heart 2020, 7,* e001271. [CrossRef]

10. Otto, C.M.; Kuusisto, J.; Reichenbach, D.D.; Gown, A.M.; O’Brien, K.D. Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies. *Circulation 1994, 90, 844–853.* [CrossRef]

11. Lindroos, M.; Kupari, M.; Valvanne, J.; Strandberg, T.; Heikkilä, J.; Tilvis, R. Factors associated with calcific aortic valve degeneration in the elderly. *Eur. Heart J.* 1994, 15, 865–870. [CrossRef] [PubMed]

12. Arnold, S.V.; Afifalo, J.; Speratus, J.A.; Tang, Y.; Baron, S.J.; Jones, P.G.; Reardon, M.J.; Yakubov, S.J.; Adams, D.H.; Cohen, D.J. Prediction of Poor Outcome After Transcatheter Aortic Valve Replacement. *J. Am. Coll. Cardiol. 2016, 68, 1868–1877.* [CrossRef]

13. Edwards, F.H.; Cohen, D.J.; O’Brien, S.M.; Peterson, E.D.; Mack, M.J.; Shahian, D.M.; Grover, F.L.; Tuzcu, E.M.; Thurani, V.H.; Carroll, J.; et al. Development and Validation of a Risk Prediction Model for In-Hospital Mortality After Transcatheter Aortic Valve Mortality. *JAMA Cardiol.* 2016, 1, 46–52. [CrossRef] [PubMed]

14. Minamino-Muta, E.; Kato, T.; Morimoto, T.; Taniguchi, T.; Ando, K.; Kanamori, N.; Murata, K.; Kitai, T.; Kawase, Y.; Miyake, M.; et al. A risk prediction model in asymptomatic patients with severe aortic stenosis: CURRENT-AS risk score. *Eur. Heart J.—Qual. Care 2020, 6,* 166–174. [CrossRef] [PubMed]

15. Braunwald, E. Aortic Stenosis: Then and Now. *Circulation 2018, 137, 2099–2100.* [CrossRef] [PubMed]

16. Sundt, T.M.; Bailey, M.S.; Moon, M.R.; Mendeloff, E.N.; Huddleston, C.B.; Pasque, M.K.; Barner, H.B.; Gay, W.A., Jr. Quality of life after aortic valve replacement at the age of >80 years. *Circulation 2000, 102 (Suppl. 3), Iii-70–Iii–74.* [CrossRef]

17. Deutsch, M.-A.; Bleiziffer, S.; Elhmidi, Y.; Piazza, N.; Voss, B.; Lange, R.; Krane, M. Beyond Adding Years to Life: Health-related Quality-of-life and Functional Outcomes in Patients with Severe Aortic Valve Stenosis at High Surgical Risk Undergoing Transcatheter Aortic Valve Replacement. *Curr. Cardiol. Rev. 2013, 9,* 281–294. [CrossRef] [PubMed]

18. Bevan, G.H.; Zidar, D.A.; Josephson, R.A.; Al-Kindi, S.G. Mortality Due to Aortic Stenosis in the United States, 2008-2017. *JAMA 2019, 321,* 2236-2238. [CrossRef] [PubMed]

19. Bach, D.S.; Siao, D.; Girard, S.E.; Duvernoy, C.; McCallister, B.D., Jr.; Gualano, S.K. Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement: The potential role of subjectively overestimated operative risk. *Circ. Cardiovasc. Qual. Outcomes 2009, 2,* 533–539. [CrossRef]

20. Beydoun, A.A.; Beydoun, M.A.; Liang, H.; Dore, G.A.; Shaked, D.; Zonderman, A.B.; Eid, S.M. Sex, Race, and Socioeconomic Disparities in Patients With Aortic Stenosis (from a Nationwide Inpatient Sample). *Am. J. Cardiol. 2016, 118,* 860–865. [CrossRef]

21. Baumgartner, H.; Falk, V; Bax, J.J.; De Bonis, M.; Hamm, C.; Holm, P.; Jung, B.; Lancellotti, P.; Lansac, E.; Rodriguez Muñoz, D.; et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur. Heart J.* 2017, 38, 2739–2791. [CrossRef] [PubMed]

22. Shtatland, E.S.; Kleinman, K.; Cain, E.M. Model Building in PROC PHREG with Automatic Variable Selection and Information Criteria; SUGI ’30 Proceedings, Paper 206-30; SAS Institute; Cary, NC, USA, 2004.

23. Sullivan, L.M.; Massaro, J.M.; D’Agostino, R.B., Sr. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. *Stat. Med. 2004, 23,* 1631–1660. [CrossRef] [PubMed]

24. Nishimura, R.A.; Otto, C.M.; Bonow, R.O.; Carabello, B.A.; Erwin, J.P., 3rd; Fleisher, L.A.; Jneid, H.; Mack, M.J.; McLeod, C.J.; O’Gara, P.T.; et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation 2017, 135,* e1159–e1195. [CrossRef]
25. Freed, B.H.; Sugeng, L.; Furlong, K.; Mor-Avi, V.; Raman, J.; Jeevanandam, V.; Lang, R.M. Reasons for Nonadherence to Guidelines for Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Potential Solutions. *Am. J. Cardiol.* 2010, 105, 1339–1342. [CrossRef] [PubMed]

26. Charlson, E.; Legedza, A.T.; Hamel, M.B. Decision-making and outcomes in severe symptomatic aortic stenosis. *J. Hear. Valve Dis.* 2006, 15, 312.

27. Ng, A.C.; Delgado, V.; Bertini, M.; Antoni, M.L.; van Bommel, R.J.; Van Rijnsoever, E.P.; Van Der Kley, F.; Ewe, S.H.; Witkowski, T.; Auger, D.; et al. Alterations in multidirectional myocardial functions in patients with aortic stenosis and preserved ejection fraction: A two-dimensional speckle tracking analysis. *Eur. Heart J.* 2011, 32, 1542–1550. [CrossRef] [PubMed]

28. Li, S.X.; Patel, N.K.; Flannery, L.D.; Selberg, A.; Kandanelly, R.R.; Morrison, F.J.; Kim, J.; Tanguturi, V.K.; Crousillat, D.R.; Shaqdan, A.W.; et al. Trends in Utilization of Aortic Valve Replacement for Severe Aortic Stenosis. *J. Am. Coll. Cardiol.* 2022, 79, 864–877. [CrossRef]